Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...

Toxoplasmosis

Toxoplasmosis

Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Casual and close social contacts are important; also for tuberculosis.

American journal of respiratory and critical care medicine·2026

Same author

Verification of emerging genomic mutations in Mycobacterium tuberculosis allows transmission chains to be distinguished in an epidemiological typing cluster extending over thirty years.

PloS one·2025

Same author

Phylodynamic assessment of SNP distances from whole genome sequencing for determining Mycobacterium tuberculosis transmission.

Scientific reports·2025

Same author

Azithromycin as Host-Directed Therapy for Pulmonary Tuberculosis: A Randomized Pilot Trial.

The Journal of infectious diseases·2025

Same author

A composite reference standard is needed for bedaquiline antimicrobial susceptibility testing for <i>Mycobacterium tuberculosis</i> complex.

The European respiratory journal·2024

Same author

Characteristic SNPs defining the major multidrug-resistant <i>Mycobacterium tuberculosis</i> clusters identified by EuSeqMyTB to support routine surveillance, EU/EEA, 2017 to 2019.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2024

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

Amplicon Sequencing using the Long-Read Sequencing Technologies

Amplicon Sequencing using the Long-Read Sequencing Technologies

Published on: August 29, 2025

Retooling national TB control programmes (NTPs) with new diagnostics: the NTP perspective.

Sanne C van Kampen¹, Andrew R Ramsay, Richard M Anthony

¹UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, Geneva, Switzerland. sanne.vankampen@gmail.com

|July 28, 2010

Summary

About half of high-burden countries use new TB diagnostics, with implementation often tied to WHO endorsement. Challenges exist, and a package approach may aid adoption.

More Related Videos

Matrix-based DNA Extraction for Targeted Next-Generation Sequencing on Decontaminated Sputum Samples

Matrix-based DNA Extraction for Targeted Next-Generation Sequencing on Decontaminated Sputum Samples

Published on: June 6, 2025

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Published on: April 9, 2012

Related Experiment Videos

Last Updated: Jun 10, 2026

Amplicon Sequencing using the Long-Read Sequencing Technologies

Amplicon Sequencing using the Long-Read Sequencing Technologies

Published on: August 29, 2025

Matrix-based DNA Extraction for Targeted Next-Generation Sequencing on Decontaminated Sputum Samples

Matrix-based DNA Extraction for Targeted Next-Generation Sequencing on Decontaminated Sputum Samples

Published on: June 6, 2025

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Published on: April 9, 2012

Area of Science:

Public Health
Infectious Disease Diagnostics
Global Health Policy

Background:

Significant delays exist between policy development and implementation of new tuberculosis (TB) diagnostics.
National TB Program (NTP) managers' insights are crucial for understanding TB diagnostic implementation progress, opportunities, and challenges.

Purpose of the Study:

To gather information from NTP managers regarding the implementation of new TB diagnostic tools in high-burden countries.
To identify progress, opportunities, and challenges associated with adopting new TB diagnostic recommendations.

Main Methods:

Questionnaires were distributed to NTP managers in high-burden TB countries.
A subset of NTP managers was interviewed to gather detailed information.

Main Results:

Approximately 50% of high-burden TB countries are utilizing WHO-recommended TB diagnostic tools.
Implementation of new diagnostics is largely contingent upon official World Health Organization (WHO) endorsement.
While adoption at reference laboratory level is planned, optimizing smear microscopy at lower service levels receives less focus.
NTP managers reported various challenges hindering the implementation of new diagnostic tools.

Conclusions:

Providing NTP managers with comprehensive information on obstacles and benefits is essential for rational adoption of new diagnostics.
A unified recommendation for a package of diagnostic tools may streamline implementation in high-burden TB countries.